Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
This study has been completed.
Study NCT00297362 Information provided by Janssen Cilag Pharmaceutica S.A.C.I., Greece
First Received: February 24, 2006 Last Updated: September 25, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer Disease
Dementia
Nervous System Diseases
Mental Disorders
Brain Diseases
More general conditions related to this trial
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Neurodegenerative Diseases
Tauopathies
Interventions listed in this trial
galantamine
More general drug interventions related to this trial
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Parasympathomimetics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Janssen Cilag Pharmaceutica S.A.C.I., Greece
Back to top of Main Content
